Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Terapia Assistita da Psilocibina Randomizzata

28 settembre 2026 aggiornato da: Anna Wise, Emory University

La sicurezza e l'accettabilità della psilocibina con supporto e con terapia di esposizione prolungata massificata per il PTSD

This pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms. Participants will be randomized into two different treatment groups, allowing the investigators to directly compare PE augmented with psilocybin and psilocybin-assisted psychotherapy.

Panoramica dello studio

Descrizione dettagliata

The Primary objective is to pilot and investigate tolerability, safety, and acceptability of psilocybin-assisted supportive therapy and psilocybin-assisted massed prolonged exposure (PE) therapy and conduct exploratory analyses related to comparative effectiveness of these treatments, including preliminary outcomes from pre-treatment to 1-month follow-up on post-traumatic stress disorder (PTSD) symptoms. Safety and tolerability of the treatment will be assessed and evaluated using the Swiss Psychedelic Side Effects Inventory (SPSI), Psychedelic-assisted Therapy After Effects (PATAE), and the Accessibility Questionnaire (AQ).

The study will also evaluate the effect of psilocybin and massed exposure therapy using Subjective Units of Distress (SUDS) during imaginal exposure sessions; to assess self-reported PTSD and depression symptoms across treatment and investigate effect on fear extinction learning and fear extinction recall as assessed via fear potentiated startle. Given that this is a pilot study with small sample, analyses will be preliminary.

Tipo di studio

Interventistico

Iscrizione (Stimato)

150

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Jessica Maples-Keller, PhD
  • Numero di telefono: 404-778-2075
  • Email: jmaple2@emory.edu

Backup dei contatti dello studio

Luoghi di studio

    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30322
        • Reclutamento
        • Emory University Hospital
        • Contatto:
          • Jessica Maples-Keller, PhD
          • Numero di telefono: 404-778-2075
          • Email: jmaple2@emory.edu
        • Investigatore principale:
          • Anna Wise, PhD
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Eligible participants must be over the age of 18. They must self-identify as military veterans, reservists, National Guard members, or active-duty servicemembers. Additionally, they must be seeking treatment for PTSD, which will be confirmed by a CAPS-5-R assessment. The criteria below will be applicable to all participants, regardless of study treatment arm.

Inclusion Criteria

  1. Meet criteria for PTSD due to trauma occurring at least 3 months prior based on CAPS-5-R diagnostic scoring rules.
  2. Able to speak and read English (due to standardization of outcome measures).
  3. Willingness of participant to sign a release for the investigators to communicate with their primary care or mental health providers, if indicated
  4. Are 18 years and older.
  5. Are able to swallow pills.
  6. Agree to have study visits video and/or audio recorded, including Medicine Session, Independent Rater assessments, and non-drug psychotherapy sessions.
  7. Must provide a contact (relative, spouse, close friend, or other support person) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.
  8. Must agree to inform the investigators within 48 hours of any medical conditions and procedures.
  9. If able to become pregnant, participants must have a negative pregnancy test prior to study entry, at study entry, and prior to each Medicine Session. They must agree to use highly effective birth control for a month prior to the Medicine session and through 10 days after the Medicine session.
  10. Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to Medicine Session, not participate in any other interventional clinical trials during the duration of the treatment, and agree not to operate their vehicles (or heavy machinery) up to 24 hours after Medicine Session, and commit to medication dosing, therapy, and study procedures.

Exclusion Criteria

  1. Are not able to give adequate informed consent.

  2. Have a family history bipolar disorder type 1 or a psychotic disorder in first degree relatives.

  3. Have any current problem which, in the opinion of the investigator or Medical Monitor, might interfere with participation.

  4. Have hypersensitivity to any ingredient of the IMP (Investigational Medicinal Product).

  5. Have a history of or current bipolar type 1 disorder, primary psychotic disorder (e.g., schizophrenia), or secondary psychotic features (i.e., Major Depressive disorder with psychotic features.

  6. Have met criteria at any time during their life for amphetamine or cocaine substance use disorder or any drug of abuse the study physician determines to be unfit for the study.

  7. Meet criteria for current (past 3 months) moderate or severe substance use disorder, as defined by 4 or more DSM SUD criteria symptoms.

  8. Have a positive screen for any drug of abuse (amphetamines, etc.) on drug test administered in local community or on site unless being taken as prescribed by a physician.

  9. Any participant presenting current serious suicide risk, as determined through psychiatric interview and clinical judgment of the investigator will be excluded;

    1. Suicidal ideation score of 4 or greater within the last 6 months.
    2. Any suicidal behavior, including suicide attempts or preparatory acts, within the last 6 months of the assessment
    3. However, history of suicide attempts is not an exclusion.
  10. Require ongoing concomitant therapy with a psychiatric medication with exceptions described in protocol section on Concomitant Medications.

    Medical History

  11. Have a history of any medical condition that could make receiving a sympathomimetic drug harmful because of increases in blood pressure and heart rate, or any medical condition the study physician believes would pose a safety risk or interfere with the effects of the treatment.

    1. This includes, but is not limited to, a history of myocardial infarction, cerebrovascular accident, or aneurysm.
    2. Participants with other stable chronic medical problems may be enrolled if the site physician believes would not significantly increase the risk of Psilocybin administration or be likely to produce significant symptoms during the study that could interfere with study participation or be confused with side effects of the IMP.
  12. Have any unstable medical or central nervous system-related illness that would interfere with participation.

  13. Systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90 mmHg, measured in the supine position after at least five minutes at rest. If the initial blood pressure is >= 140/90 mmHg, up to three additional attempts before dosing visit are permitted. The study physician will manage blood pressure monitoring from baseline through 10 days after drug administration.

  14. Have a history of clinically significant arrhythmia, other than premature atrial contractions (PACs) or occasional PVCs in the absence of ischemic heart disease, within 12 months of screening.

    a. Participants with a history of atrial fibrillation, atrial tachycardia, atrial flutter or paroxysmal supraventricular tachycardia or any other arrhythmia associated with a bypass tract may be enrolled only if they have been successfully treated with ablation and have not had recurrent arrhythmia for at least one year off all antiarrhythmic drugs and confirmed by a cardiologist.

  15. Have a marked Baseline prolongation of QT/QTc interval e.g., repeated demonstration of a QTc interval > 450 milliseconds (ms) in males and >470 ms in females. For transgender or non-binary participants, QTc interval will be evaluated based on sex assigned at birth.

  16. Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, family history of Long QT Syndrome).

  17. Have significant liver enzyme elevations as evidenced by total bilirubin >1.5mg/dL and/or ALT and AST (>two times upper limit of normal [ULN]) per baseline laboratory test.

  18. Creatinine clearance: <30 mL/min)

  19. Non-ambulatory or require two-person assistance with transfers (Fall risk)

  20. Body Mass Index (BMI) <18

  21. Are pregnant or nursing

  22. fMRI Scan Exclusions Only: History of cranial surgery, metallic particles in the eye or head (exclusive of mouth), implanted cardiac pacemaker or any intra-cardiac lines, implanted neurostimulators, intra-cranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or implanted medical pumps.

    1. NOTE: these ineligibility criteria preclude participants from undergoing a fmri scan but does not exclude them from the primary study participant and they may proceed without fMRI.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Group 1: Psilocybin combined with supportive therapy

All participants will receive a single 25 mg dose of psilocybin during the experimental session, which occurs during to their respective therapy model.

Then, participants will receive 2 support (integrative) therapy sessions that will be 1 week apart. In between these sessions, subjects will complete a series of online surveys to track treatment progress.

25 mg

Altri nomi:
  • 3-[2-(Dimetilammino)etil]-1H-indol-4-il diidrogeno fosfato

Treatment includes non-directive psychological support across the preparatory, dosing, and integration sessions. Preparatory sessions include psychoeducation regarding psilocybin's subjective effects and establish strategies for psilocybin related support, including boundaries around physical touch. Therapists encourage setting intention for dosing day, and practicing experiential exercises. Integration sessions include processing the participant's experience of their psilocybin administration session. Therapists will support participants in identifying activities for ongoing integration outside of sessions. The standard care for supportive therapy will be modeled in this study.

Sperimentale: Group 2: Psilocybin combined with massed prolonged exposure (PE) therapy

All participants will receive a single 25 mg dose of psilocybin during the experimental session, followed by 10 prolonged exposure (PE) therapy sessions for 10 days. In between these sessions, participants will complete a series of online surveys to track treatment progress.

25 mg

Altri nomi:
  • 3-[2-(Dimetilammino)etil]-1H-indol-4-il diidrogeno fosfato

Prolonged Exposure (PE) Therapy will be conducted for 10 sessions. They will consist of repeated exposures to trauma memories (imaginal exposure) consistent with the manualized protocol for massed exposure therapy. Also consistent with this treatment manual, participants will listen to imaginal exposures and conduct in real life exposures outside of PE sessions for "homework". The standard care for PE therapy will be modeled in this study.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in PTSD symptoms based on CAPS-5-R total severity score
Lasso di tempo: Baseline, 1-month post-intervention

PTSD symptoms will be evaluated using the Revised Clinician-Administered PTSD Scale for DSM-5, that refers to 20 core symptoms as CAPS-5, each rated on a 0-4 severity scale (0 = absent to 4 = extremely severe), combining frequency and intensity. Total possible score range is 0 to 80 with higher scores correlating with worse outcome.

Baseline, 1-month post-intervention
Change in PCL-5 score
Lasso di tempo: Baseline, 1, 6 and 12 months post-intervention

The PCL-5 is a 20-item self-report measure of DSM-5 PTSD symptoms. Scores on the PCL range from 0 to 80, with higher scores indicating higher symptom severity, and a cutoff of 33 indicating clinical levels of PTSD symptoms.

Baseline, 1, 6 and 12 months post-intervention
Depression symptoms (PHQ-9)
Lasso di tempo: Baseline, 1, 6 and 12 months post-intervention

The PHQ-9 is a 9-item self-report measure of depressive symptoms. A score of 10 or above indicative of a possible major depressive episode, and it provides a measure of severity of these symptoms. Total possible score range is 0-29, higher score correlates with worse outcome.

Baseline, 1, 6 and 12 months post-intervention

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Anna Wise, PhD, Emory University

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

8 giugno 2026

Completamento primario (Stimato)

1 marzo 2027

Completamento dello studio (Stimato)

1 marzo 2027

Date di iscrizione allo studio

Primo inviato

8 gennaio 2026

Primo inviato che soddisfa i criteri di controllo qualità

8 gennaio 2026

Primo Inserito (Effettivo)

12 gennaio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

1 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi